Ixabepilon en Temsirolimus bij de behandeling van patiënten met solide tumoren die uitgezaaid zijn of niet operatief kunnen worden verwijderd
Fase I-studie van ixabepilon en temsirolimus bij volwassen patiënten met vergevorderde solide tumoren
This phase I trial studies the side effects and best dose of ixabepilone and temsirolimus in treating patients with solid tumors that have spread from the primary site to other places in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ixabepilone together with temsirolimus may kill more tumor cells.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To determine the maximally tolerated dose (MTD) of the combination of ixabepilone and temsirolimus in patients with advanced solid tumors.
II. To describe toxicity profiles associated with the combination of ixabepilone and temsirolimus.
III. To assess preliminary efficacy of the combination of ixabepilone and temsirolimus.
OUTLINE: This is a dose-escalation study.
Patients receive ixabepilone intravenously (IV) over 3 hours on day 1 and temsirolimus IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 3 months.
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32224-9980
- Mayo Clinic in Florida
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Mayo Clinic in Rochester
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adult patients with histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard curative measures or other therapy that provide survival benefit do not exist or are no longer effective
- Patients may not have had more than two systemic therapeutic regimens in the metastatic disease setting with the following exceptions: hormonal therapy (e.g. tamoxifen, aromatase inhibitors, anti-androgen therapy, etc.)
- Patients with non-measurable, but assessable, disease will be allowed
- Absolute neutrophil count >= 1500/mcL
- Hemoglobin >= 9.0 g/dL
- Platelets >= 100,000/mcL
- Total bilirubin < 1.5 mg/dL
- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) or serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x institutional upper limit of normal (ULN) in the absence of hepatic metastasis; SGPT (ALT) =< 3 x ULN or SGOT (AST) =< 5 x ULN in the presence of hepatic metastasis
- Creatinine =< 1.5 x ULN
- International normalized ratio (INR) =< 1.4 for patients not on warfarin (Coumadin)
- INR range of 2.0-3.0 for patients on therapeutic doses of warfarin (Coumadin)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
- Ability to provide informed consent
- Willingness to return to a Mayo Clinic institution for follow up
- Life expectancy >= 84 days (12 weeks)
- Women of childbearing potential only: negative serum pregnancy test done =< 7 days prior to registration
Exclusion Criteria:
-
Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes or with hemoglobin A1c (HbA1C) > 8, or psychiatric illness/social situations that would limit compliance with study requirements
-
Any of the following prior therapies:
- Chemotherapy =< 28 days prior to registration
- Mitomycin C/nitrosoureas =< 42 days prior to registration
- Immunotherapy =< 28 days prior to registration
- Biologic therapy =< 28 days prior to registration
- Radiation therapy =< 28 days prior to registration
- Radiation to > 25% of bone marrow
-
Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment
-
New York Heart Association classification III or IV
-
Known central nervous system (CNS) metastases or seizure disorder; patients with known brain metastases that have been successfully treated and stable for > 6 months without requirement for corticosteroids and without seizure activity will be eligible
-
Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception
-
Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)
-
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
-
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive
-
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
-
History of myocardial infarction =< 168 days (6 months), or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
-
>= Grade 2 sensory neuropathy
-
>= Grade 2 hypertriglyceridemia
-
>= Grade 2 hypercholesterolemia
-
Patients on medication considered strong cytochrome P450 3A4 (CYP3A4) inducers (efavirenz, nevirapine, carbamazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's wort) or CYP3A4 inhibitors (indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, telithromycin) unless the medication can be substituted with another agent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Treatment (ixabepilone, temsirolimus)
Patients receive ixabepilone IV over 3 hours on day 1 and temsirolimus IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given IV
Andere namen:
Given IV
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
MTD van de combinatie van ixabepilon en temsirolimus, gedefinieerd als het dosisniveau onder de laagste dosis dat dosisbeperkende toxiciteit induceert bij ten minste een derde van de patiënten (ten minste 2 van maximaal 6 nieuwe patiënten)
Tijdsspanne: 21 dagen
|
21 dagen
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Tijd tot falen van de behandeling
Tijdsspanne: Van registratie tot documentatie van progressie, onaanvaardbare toxiciteit of weigering van deelname door de patiënt, beoordeeld tot 3 maanden
|
Van registratie tot documentatie van progressie, onaanvaardbare toxiciteit of weigering van deelname door de patiënt, beoordeeld tot 3 maanden
|
|
|
Tijd tot eventuele behandelingsgerelateerde toxiciteit
Tijdsspanne: Tot 3 maanden
|
Tot 3 maanden
|
|
|
Tijd tot behandelingsgerelateerde graad 3+ toxiciteit
Tijdsspanne: Tot 3 maanden
|
Tot 3 maanden
|
|
|
Tijd tot hematologische nadirs (witte bloedcellen, absoluut aantal neutrofielen, bloedplaatjes)
Tijdsspanne: Tot 3 maanden
|
Tot 3 maanden
|
|
|
Tijd voor progressie
Tijdsspanne: Tot 3 maanden
|
Tot 3 maanden
|
|
|
Incidence of adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Tijdsspanne: Up to 3 months
|
The number and severity of all adverse events (overall, by dose-level, and by tumor group) will be tabulated and summarized in this patient population. |
Up to 3 months
|
|
Incidence of overall toxicity graded according to Common Toxicity Criteria standard grading
Tijdsspanne: Up to 3 months
|
Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses. |
Up to 3 months
|
|
Best response, defined to be the best objective status recorded from the start of the treatment until disease progression/recurrence
Tijdsspanne: Up to 3 months
|
Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall and by tumor group). |
Up to 3 months
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Keith C Bible, Mayo Clinic
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- NCI-2012-02907
- P30CA015083 (Subsidie/contract van de Amerikaanse NIH)
- U01CA069912 (Subsidie/contract van de Amerikaanse NIH)
- UM1CA186686 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2012-02907 (Register-ID: CTRP (Clinical Trial Reporting Program))
- NCI-2012-01136
- CDR0000702380
- NCI-2011-01140
- MC1013 (Andere identificatie: Mayo Clinic in Rochester)
- 8814 (Andere identificatie: CTEP)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .